| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Loss before income tax benefit (expense) | -128,393 | 123,531 | -146,822 | -144,101 |
| Income tax benefit (expense) | 213 | -20 | 116 | -3,621 |
| Net loss | -128,606 | 123,551 | -146,938 | -140,480 |
| Basic net loss per share (in dollars per share) | -0.8 | 0.78 | -0.93 | -0.95 |
| Diluted net loss per share (in dollars per share) | -0.8 | 0.7 | -0.93 | -0.95 |
| Shares used in computing basic net loss per share (in shares) | 159,765,000 | 159,137,000 | 158,735,000 | 148,593,000 |
| Shares used in computing diluted net loss per share (in shares) | 159,765,000 | 182,331,000 | 158,735,000 | 148,593,000 |
IONIS PHARMACEUTICALS INC (IONS)
IONIS PHARMACEUTICALS INC (IONS)